secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2022-05-17T23:59:59+00:00
Accession:  0001193125-22-152247
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Therapeutics enters ATM equity distribution agreement for up to $9.8M through Piper Sandler
--------------------------------------------------------------------------------

- Aggregate offering price up to $9,801,287 of common stock; sales at market prices via Piper Sandler.
- Agent receives 3.0% commission on gross proceeds; expense reimbursement up to $75k upfront + $15k per quarter.
- Sales made under existing shelf registration (Form S-3, File 333-262551) effective Feb 2022.
- Company has no obligation to sell; may suspend or terminate the agreement at any time.
- Customary representations, warranties, and indemnification provisions included.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312522152247/0001193125-22-152247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312522152247/d288031d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-152247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer